Trial Profile
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Jan 2017 Results of retrospective analysis assessing response rate and survival in patients with right-sided versus left-sided tumors, presented at the 2017 Gastrointestinal Cancers Symposium
- 13 Mar 2011 New trial record